A Phase 2 Safety and Efficacy Study Evaluating CS-101 in Participants With β-Thalassemia Major

Phase 2 Not yet recruiting 20 enrolled CorrectSequence Therapeutics Co., Ltd

NaSingle-groupOpen-labelTreatment

Summary

The goal of this open label, single-arm clinical study is to learn about the safety and efficacy of CS-101 in treating patients with β-Thalassemia Major

Timeline

Start: 2026-04-05
Primary completion: 2028-01-31
Completion: 2028-07-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CS-101	Cell therapy	—	—

A Phase 2 Safety and Efficacy Study Evaluating CS-101 in Participants With β-Thalassemia Major

Summary

Timeline

Drugs

Indications